{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T22:43:14Z","timestamp":1772145794582,"version":"3.50.1"},"publisher-location":"Berlin, Heidelberg","reference-count":302,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783662463437","type":"print"},{"value":"9783662463444","type":"electronic"}],"license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/7854_2013_250","type":"book-chapter","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T03:08:19Z","timestamp":1385435299000},"page":"161-201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic Strategies for Huntington\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Ladislav","family":"Mrzljak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Munoz-Sanjuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,27]]},"reference":[{"key":"250_CR1","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1021\/jm9608467","volume":"40","author":"HS Ahn","year":"1997","unstructured":"Ahn HS, Bercovici A, Boykow G et al (1997) Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity. J Med Chem 40:2196\u20132210","journal-title":"J Med Chem"},{"key":"250_CR2","doi-asserted-by":"crossref","first-page":"29427","DOI":"10.1074\/jbc.M109.013193","volume":"284","author":"CT Aiken","year":"2009","unstructured":"Aiken CT, Steffan JS, Guerrero CM et al (2009) Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J Biol Chem 284:29427\u201329436","journal-title":"J Biol Chem"},{"key":"250_CR3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","volume":"12","author":"RL Albin","year":"1989","unstructured":"Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366\u2013375","journal-title":"Trends Neurosci"},{"key":"250_CR4","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1523\/JNEUROSCI.5631-03.2004","volume":"24","author":"M Alkondon","year":"2004","unstructured":"Alkondon M, Pereira EF, Yu P et al (2004) Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus. J Neurosci 24:4635\u20134648","journal-title":"J Neurosci"},{"key":"250_CR5","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.bcp.2011.06.004","volume":"82","author":"M Alkondon","year":"2011","unstructured":"Alkondon M, Pereira EF, Albuquerque EX (2011) Endogenous activation of nAChRs and NMDA receptors contributes to the excitability of CA1 stratum radiatum interneurons in rat hippocampal slices: effects of kynurenic acid. Biochem Pharmacol 82:842\u2013851","journal-title":"Biochem Pharmacol"},{"key":"250_CR6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jchemneu.2009.02.001","volume":"37","author":"KL Allen","year":"2009","unstructured":"Allen KL, Waldvogel HJ, Glass M et al (2009) Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington\u2019s disease. J Chem Neuroanat 37:266\u2013281","journal-title":"J Chem Neuroanat"},{"key":"250_CR7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/ng1095-115","volume":"11","author":"MA Andrade","year":"1995","unstructured":"Andrade MA, Bork P (1995) HEAT repeats in the Huntington\u2019s disease protein. Nat Genet 11:115\u2013116","journal-title":"Nat Genet"},{"key":"250_CR8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1755-5949.2010.00134.x","volume":"16","author":"VM Andre","year":"2010","unstructured":"Andre VM, Cepeda C, Levine MS (2010) Dopamine and glutamate in Huntington\u2019s disease: a balancing act. CNS Neurosci Ther 16:163\u2013178","journal-title":"CNS Neurosci Ther"},{"key":"250_CR9","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1460-9568.1996.tb01314.x","volume":"8","author":"E Arenas","year":"1996","unstructured":"Arenas E, Akerud P, Wong V et al (1996) Effects of BDNF and NT-4\/5 on striatonigral neuropeptides or nigral GABA neurons in vivo. Eur J Neurosci 8:1707\u20131717","journal-title":"Eur J Neurosci"},{"key":"250_CR10","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s10571-011-9725-y","volume":"31","author":"L Arregui","year":"2011","unstructured":"Arregui L, Benitez JA, Razgado LF et al (2011) Adenoviral astrocyte-specific expression of BDNF in the striata of mice transgenic for Huntington\u2019s disease delays the onset of the motor phenotype. Cell Mol Neurobiol 31:1229\u20131243","journal-title":"Cell Mol Neurobiol"},{"key":"250_CR11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nchembio.582","volume":"7","author":"RS Atwal","year":"2011","unstructured":"Atwal RS, Desmond CR, Caron N et al (2011) Kinase inhibitors modulate huntingtin cell localization and toxicity. Nat Chem Biol 7:453\u2013460","journal-title":"Nat Chem Biol"},{"key":"250_CR12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.chembiol.2011.12.020","volume":"19","author":"B Baldo","year":"2012","unstructured":"Baldo B, Paganetti P, Grueninger S et al (2012) TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington\u2019s disease. Chem Biol 19:264\u2013275","journal-title":"Chem Biol"},{"key":"250_CR13","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1111\/febs.12329","volume":"280","author":"M Bari","year":"2013","unstructured":"Bari M, Battista N, Valenza M et al (2013) In vitro and in vivo models of Huntington\u2019s disease show alterations in the endocannabinoid system. FEBS J 280:3376\u20133388","journal-title":"FEBS J"},{"key":"250_CR14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neurobiolaging.2012.07.018","volume":"34","author":"RT Bartus","year":"2013","unstructured":"Bartus RT, Baumann TL, Brown L et al (2013) Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating \u201cclinical proof-of-concept\u201d for AAV-neurturin (CERE-120) in Parkinson\u2019s disease. Neurobiol Aging 34:35\u201361","journal-title":"Neurobiol Aging"},{"key":"250_CR15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1006\/nbdi.1998.0168","volume":"4","author":"MW Becher","year":"1998","unstructured":"Becher MW, Kotzuk JA, Sharp AH et al (1998) Intranuclear neuronal inclusions in Huntington\u2019s disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 4:387\u2013397","journal-title":"Neurobiol Dis"},{"key":"250_CR16","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1124\/dmd.112.046532","volume":"40","author":"MG Beconi","year":"2012","unstructured":"Beconi MG, Yates D, Lyons K et al (2012a) Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048. Drug Metab Dispos 40:2297\u20132306","journal-title":"Drug Metab Dispos"},{"key":"250_CR17","doi-asserted-by":"crossref","first-page":"e44498","DOI":"10.1371\/journal.pone.0044498","volume":"7","author":"M Beconi","year":"2012","unstructured":"Beconi M, Aziz O, Matthews K et al (2012b) Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. PLoS One 7:e44498","journal-title":"PLoS One"},{"key":"250_CR18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1747-0285.2009.00901.x","volume":"74","author":"D Beher","year":"2009","unstructured":"Beher D, Wu J, Cumine S et al (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74:619\u2013624","journal-title":"Chem Biol Drug Des"},{"key":"250_CR19","doi-asserted-by":"crossref","first-page":"e5747","DOI":"10.1371\/journal.pone.0005747","volume":"4","author":"CL Benn","year":"2009","unstructured":"Benn CL, Butler R, Mariner L et al (2009) Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6\/2 mouse model of Huntington\u2019s disease. PLoS One 4:e5747","journal-title":"PLoS One"},{"key":"250_CR20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00004850-198807000-00006","volume":"3","author":"A Bertolino","year":"1988","unstructured":"Bertolino A, Crippa D, di Dio S et al (1988) Rolipram versus imipramine in inpatients with major, minor or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach. Int Clin Psychopharmacol 3:245\u2013253","journal-title":"Int Clin Psychopharmacol"},{"key":"250_CR21","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/ncomms3031","volume":"4","author":"D Besusso","year":"2013","unstructured":"Besusso D, Geibel M, Kramer D et al (2013) BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior. Nat Commun 4:2031","journal-title":"Nat Commun"},{"key":"250_CR22","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/mds.22601","volume":"24","author":"KM Biglan","year":"2009","unstructured":"Biglan KM, Ross CA, Langbehn DR et al (2009) Motor abnormalities in premanifest persons with Huntington\u2019s disease: the PREDICT-HD study. Mov Disord 24:1763\u20131772","journal-title":"Mov Disord"},{"key":"250_CR23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","volume":"134","author":"C Blazquez","year":"2011","unstructured":"Blazquez C, Chiarlone A, Sagredo O et al (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington\u2019s disease. Brain 134:119\u2013136","journal-title":"Brain"},{"key":"250_CR24","doi-asserted-by":"crossref","first-page":"e20696","DOI":"10.1371\/journal.pone.0020696","volume":"6","author":"A Bobrowska","year":"2011","unstructured":"Bobrowska A, Paganetti P, Matthias P et al (2011) Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6\/2 mouse model of Huntington\u2019s disease. PLoS One 6:e20696","journal-title":"PLoS One"},{"key":"250_CR25","doi-asserted-by":"crossref","first-page":"e34805","DOI":"10.1371\/journal.pone.0034805","volume":"7","author":"A Bobrowska","year":"2012","unstructured":"Bobrowska A, Donmez G, Weiss A et al (2012) SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington\u2019s disease phenotypes in vivo. PLoS One 7:e34805","journal-title":"PLoS One"},{"key":"250_CR26","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.neuropharm.2004.07.040","volume":"47","author":"FG Boess","year":"2004","unstructured":"Boess FG, Hendrix M, van der Staay FJ et al (2004) Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47:1081\u20131092","journal-title":"Neuropharmacology"},{"key":"250_CR27","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1212\/WNL.0b013e318293e1a1","volume":"80","author":"B Borowsky","year":"2013","unstructured":"Borowsky B, Warner J, Leavitt BR et al (2013) 8OHdG is not a biomarker for Huntington disease state or progression. Neurology 80:1934\u20131941","journal-title":"Neurology"},{"key":"250_CR28","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1172\/JCI27607","volume":"116","author":"M Borrell-Pages","year":"2006","unstructured":"Borrell-Pages M, Canals JM, Cordelieres FP et al (2006) Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 116:1410\u20131424","journal-title":"J Clin Invest"},{"key":"250_CR29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/jnp.2.1.20","volume":"2","author":"J Brandt","year":"1990","unstructured":"Brandt J, Folstein SE, Wong DF et al (1990) D2 receptors in Huntington\u2019s disease: positron emission tomography findings and clinical correlates. J Neuropsychiatry Clin Neurosci 2:20\u201327","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"250_CR30","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1038\/cddis.2013.116","volume":"4","author":"V Brito","year":"2013","unstructured":"Brito V, Puigdellivol M, Giralt A et al (2013) Imbalance of p75(NTR)\/TrkB protein expression in Huntington\u2019s disease: implication for neuroprotective therapies. Cell Death Dis 4:e595","journal-title":"Cell Death Dis"},{"key":"250_CR31","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1111\/j.1476-5381.2011.01524.x","volume":"164","author":"O Bruno","year":"2011","unstructured":"Bruno O, Fedele E, Prickaerts J et al (2011) GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. Br J Pharmacol 164:2054\u20132063","journal-title":"Br J Pharmacol"},{"key":"250_CR32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.nbd.2010.02.003","volume":"39","author":"NJ Buckley","year":"2010","unstructured":"Buckley NJ, Johnson R, Zuccato C et al (2010) The role of REST in transcriptional and epigenetic dysregulation in Huntington\u2019s disease. Neurobiol Dis 39:28\u201339","journal-title":"Neurobiol Dis"},{"key":"250_CR33","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.neuropharm.2006.06.018","volume":"51","author":"Y Bureau","year":"2006","unstructured":"Bureau Y, Handa M, Zhu Y et al (2006) Neuroanatomical and pharmacological assessment of Fos expression induced in the rat brain by the phosphodiesterase-4 inhibitor 6-(4-pyridylmethyl)-8-(3-nitrophenyl) quinoline. Neuropharmacology 51:974\u2013985","journal-title":"Neuropharmacology"},{"key":"250_CR34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nbt.1598","volume":"28","author":"AB Burgin","year":"2010","unstructured":"Burgin AB, Magnusson OT, Singh J et al (2010) Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 28:63\u201370","journal-title":"Nat Biotechnol"},{"key":"250_CR35","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1098\/rstb.2011.0386","volume":"367","author":"R Cachope","year":"2012","unstructured":"Cachope R (2012) Functional diversity on synaptic plasticity mediated by endocannabinoids. Philos Trans R Soc Lond B Biol Sci 367:3242\u20133253","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"250_CR36","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cub.2011.04.028","volume":"21","author":"S Campesan","year":"2011","unstructured":"Campesan S, Green EW, Breda C et al (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington\u2019s disease. Curr Biol 21:961\u2013966","journal-title":"Curr Biol"},{"key":"250_CR37","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1523\/JNEUROSCI.1197-04.2004","volume":"24","author":"JM Canals","year":"2004","unstructured":"Canals JM, Pineda JR, Torres-Peraza JF et al (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington\u2019s disease. J Neurosci 24:7727\u20137739","journal-title":"J Neurosci"},{"key":"250_CR38","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","volume":"6","author":"E Cattaneo","year":"2005","unstructured":"Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington\u2019s disease. Nat Rev Neurosci 6:919\u2013930","journal-title":"Nat Rev Neurosci"},{"key":"250_CR39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.tcb.2009.01.005","volume":"19","author":"JP Caviston","year":"2009","unstructured":"Caviston JP, Holzbaur EL (2009) Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol 19:147\u2013155","journal-title":"Trends Cell Biol"},{"key":"250_CR40","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1523\/JNEUROSCI.2137-12.2013","volume":"33","author":"C Cepeda","year":"2013","unstructured":"Cepeda C, Galvan L, Holley SM et al (2013) Multiple sources of striatal inhibition are differentially affected in Huntington\u2019s disease mouse models. J Neurosci 33:7393\u20137406","journal-title":"J Neurosci"},{"key":"250_CR41","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cellsig.2007.10.003","volume":"20","author":"A Chandrasekaran","year":"2008","unstructured":"Chandrasekaran A, Toh KY, Low SH et al (2008) Identification and characterization of novel mouse PDE4D isoforms: Molecular cloning, subcellular distribution and detection of isoform-specific intracellular localization signals. Cell Signal 20:139\u2013153","journal-title":"Cell Signal"},{"key":"250_CR42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mcn.2012.11.011","volume":"55","author":"RK Chaturvedi","year":"2013","unstructured":"Chaturvedi RK, Beal MF (2013) Mitochondria targeted therapeutic approaches in Parkinson\u2019s and Huntington\u2019s diseases. Mol Cell Neurosci 55:101\u2013114","journal-title":"Mol Cell Neurosci"},{"key":"250_CR43","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1093\/hmg\/ddp243","volume":"18","author":"RK Chaturvedi","year":"2009","unstructured":"Chaturvedi RK, Adhihetty P, Shukla S et al (2009) Impaired PGC-1alpha function in muscle in Huntington\u2019s disease. Hum Mol Genet 18:3048\u20133065","journal-title":"Hum Mol Genet"},{"key":"250_CR44","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.clinthera.2012.06.010","volume":"34","author":"JJ Chen","year":"2012","unstructured":"Chen JJ, Ondo WG, Dashtipour K et al (2012) Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther 34:1487\u20131504","journal-title":"Clin Ther"},{"key":"250_CR45","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.nbd.2011.12.017","volume":"45","author":"V Chiodi","year":"2012","unstructured":"Chiodi V, Uchigashima M, Beggiato S et al (2012) Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington\u2019s disease. Neurobiol Dis 45:983\u2013991","journal-title":"Neurobiol Dis"},{"key":"250_CR46","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1471-4159.2005.03029.x","volume":"93","author":"SY Chou","year":"2005","unstructured":"Chou SY, Lee YC, Chen HM et al (2005) CGS21680 attenuates symptoms of Huntington\u2019s disease in a transgenic mouse model. J Neurochem 93:310\u2013320","journal-title":"J Neurochem"},{"key":"250_CR47","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","volume":"325","author":"C Choudhary","year":"2009","unstructured":"Choudhary C, Kumar C, Gnad F et al (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325:834\u2013840","journal-title":"Science"},{"key":"250_CR48","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1471-4159.2006.03807.x","volume":"97","author":"J Christofides","year":"2006","unstructured":"Christofides J, Bridel M, Egerton M et al (2006) Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington\u2019s disease or chronic brain injury. J Neurochem 97:1078\u20131088","journal-title":"J Neurochem"},{"key":"250_CR49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mds.23258","volume":"26","author":"A Ciammola","year":"2011","unstructured":"Ciammola A, Sassone J, Sciacco M et al (2011) Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington\u2019s disease. Mov Disord 26:130\u2013137","journal-title":"Mov Disord"},{"key":"250_CR50","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/gt.2012.84","volume":"20","author":"P Conforti","year":"2013","unstructured":"Conforti P (2013) Mas Monteys, A.; Zuccato, C., et al. In vivo delivery of DN:REST improves transcriptional changes of REST-regulated genes in HD mice. Gene Ther 20:678\u2013685","journal-title":"Gene Ther"},{"issue":"1","key":"250_CR51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jnc.12348","volume":"127","author":"P Conforti","year":"2013","unstructured":"Conforti P, Zuccato C, Gaudenzi G et al (2013) Binding of the repressor complex REST-mSIN3b by small molecules restores neuronal gene transcription in Huntington\u2019s disease models. J Neurochem 127(1):22\u201335","journal-title":"J Neurochem"},{"key":"250_CR52","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neuron.2010.12.035","volume":"69","author":"ZR Crook","year":"2011","unstructured":"Crook ZR, Housman D (2011) Huntington\u2019s disease: can mice lead the way to treatment? Neuron 69:423\u2013435","journal-title":"Neuron"},{"key":"250_CR53","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","volume":"24","author":"A Curtis","year":"2009","unstructured":"Curtis A, Mitchell I, Patel S et al (2009) A pilot study using nabilone for symptomatic treatment in Huntington\u2019s disease. Mov Disord 24:2254\u20132259","journal-title":"Mov Disord"},{"key":"250_CR54","doi-asserted-by":"crossref","first-page":"32695","DOI":"10.1074\/jbc.M110.133892","volume":"285","author":"H Dai","year":"2010","unstructured":"Dai H, Kustigian L, Carney D et al (2010) SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem 285:32695\u201332703","journal-title":"J Biol Chem"},{"key":"250_CR55","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1523\/JNEUROSCI.1683-10.2010","volume":"30","author":"V De Chiara","year":"2010","unstructured":"De Chiara V, Angelucci F, Rossi S et al (2010) Brain-derived neurotrophic factor controls cannabinoid CB1 receptor function in the striatum. J Neurosci 30:8127\u20138137","journal-title":"J Neurosci"},{"key":"250_CR56","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","volume":"10","author":"JG De Yebenes","year":"2011","unstructured":"De Yebenes JG, Landwehrmeyer B, Squitieri F et al (2011) Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 10:1049\u20131057","journal-title":"Lancet Neurol"},{"key":"250_CR57","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.nbd.2006.09.006","volume":"25","author":"Z Demarch","year":"2007","unstructured":"Demarch Z, Giampa C, Patassini S et al (2007) Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity. Neurobiol Dis 25:266\u2013273","journal-title":"Neurobiol Dis"},{"key":"250_CR58","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.nbd.2008.02.010","volume":"30","author":"Z DeMarch","year":"2008","unstructured":"DeMarch Z, Giampa C, Patassini S et al (2008) Beneficial effects of rolipram in the R6\/2 mouse model of Huntington\u2019s disease. Neurobiol Dis 30:375\u2013387","journal-title":"Neurobiol Dis"},{"key":"250_CR59","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0306-4522(00)00157-3","volume":"98","author":"EM Denovan-Wright","year":"2000","unstructured":"Denovan-Wright EM, Robertson HA (2000) Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington\u2019s disease mice. Neuroscience 98:705\u2013713","journal-title":"Neuroscience"},{"key":"250_CR60","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa060281","volume":"355","author":"G Deuschl","year":"2006","unstructured":"Deuschl G, Schade-Brittinger C, Krack P et al (2006) A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med 355:896\u2013908","journal-title":"N Engl J Med"},{"key":"250_CR61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nbd.2007.07.009","volume":"28","author":"MR Domenici","year":"2007","unstructured":"Domenici MR, Scattoni ML, Martire A et al (2007) Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6\/2 Huntington\u2019s disease mice. Neurobiol Dis 28:197\u2013205","journal-title":"Neurobiol Dis"},{"key":"250_CR62","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/bph.12164","volume":"169","author":"JG Doria","year":"2013","unstructured":"Doria JG, Silva FR, de Souza JM et al (2013) Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington\u2019s disease. Br J Pharmacol 169:909\u2013921","journal-title":"Br J Pharmacol"},{"key":"250_CR63","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.neuroscience.2009.06.014","volume":"163","author":"MJ Dowie","year":"2009","unstructured":"Dowie MJ, Bradshaw HB, Howard ML et al (2009) Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington\u2019s disease. Neuroscience 163:456\u2013465","journal-title":"Neuroscience"},{"key":"250_CR64","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neuroscience.2010.06.056","volume":"170","author":"MJ Dowie","year":"2010","unstructured":"Dowie MJ, Howard ML, Nicholson LF et al (2010) Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington\u2019s disease transgenic mice. Neuroscience 170:324\u2013336","journal-title":"Neuroscience"},{"key":"250_CR65","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/mds.20756","volume":"21","author":"R Dubinsky","year":"2006","unstructured":"Dubinsky R, Gray C (2006) CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington\u2019s disease. Mov Disord 21:530\u2013533","journal-title":"Mov Disord"},{"key":"250_CR66","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.biopsych.2006.11.034","volume":"62","author":"K Duff","year":"2007","unstructured":"Duff K, Paulsen JS, Beglinger LJ et al (2007) Psychiatric symptoms in Huntington\u2019s disease before diagnosis: the predict-HD study. Biol Psychiatry 62:1341\u20131346","journal-title":"Biol Psychiatry"},{"key":"250_CR67","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1176\/jnp.2010.22.2.196","volume":"22","author":"K Duff","year":"2010","unstructured":"Duff K, Paulsen JS, Beglinger LJ et al (2010) Frontal behaviors before the diagnosis of Huntington\u2019s disease and their relationship to markers of disease progression: evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci 22:196\u2013207","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"250_CR68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2009.11.025","volume":"628","author":"T Dyhring","year":"2010","unstructured":"Dyhring T, Nielsen EO, Sonesson C et al (2010) The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol 628:19\u201326","journal-title":"Eur J Pharmacol"},{"key":"250_CR69","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1073858410390378","volume":"17","author":"DE Ehrnhoefer","year":"2011","unstructured":"Ehrnhoefer DE, Sutton L, Hayden MR (2011) Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist 17:475\u2013492","journal-title":"Neuroscientist"},{"key":"250_CR70","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1172\/JCI45646","volume":"121","author":"D Eidelberg","year":"2011","unstructured":"Eidelberg D, Surmeier DJ (2011) Brain networks in Huntington disease. J Clin Invest 121:484\u2013492","journal-title":"J Clin Invest"},{"key":"250_CR71","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1093\/hmg\/ddq212","volume":"19","author":"M Faideau","year":"2010","unstructured":"Faideau M, Kim J, Cormier K et al (2010) In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington\u2019s disease subjects. Hum Mol Genet 19:3053\u20133067","journal-title":"Hum Mol Genet"},{"key":"250_CR72","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/mds.22116","volume":"23","author":"A Fasano","year":"2008","unstructured":"Fasano A, Mazzone P, Piano C et al (2008) GPi-DBS in Huntington\u2019s disease: results on motor function and cognition in a 72-year-old case. Mov Disord 23:1289\u20131292","journal-title":"Mov Disord"},{"key":"250_CR73","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/mds.20356","volume":"20","author":"AP Fawcett","year":"2005","unstructured":"Fawcett AP, Moro E, Lang AE et al (2005) Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington\u2019s disease. Mov Disord 20:371\u2013377","journal-title":"Mov Disord"},{"key":"250_CR74","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.brainres.2010.01.080","volume":"1323","author":"A Ferrante","year":"2010","unstructured":"Ferrante A, Martire A, Armida M et al (2010) Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington\u2019s disease mice. Brain Res 1323:184\u2013191","journal-title":"Brain Res"},{"key":"250_CR75","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12035-012-8315-4","volume":"46","author":"M Figiel","year":"2012","unstructured":"Figiel M, Szlachcic WJ, Switonski PM et al (2012) Mouse models of polyglutamine diseases: review and data table. Part I. Mol Neurobiol 46:393\u2013429","journal-title":"Part I. Mol Neurobiol"},{"key":"250_CR76","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0361-9230(01)00577-9","volume":"56","author":"KH Fischbeck","year":"2001","unstructured":"Fischbeck KH (2001) Polyglutamine expansion neurodegenerative disease. Brain Res Bull 56:161\u2013163","journal-title":"Brain Res Bull"},{"key":"250_CR77","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.bmc.2009.02.053","volume":"17","author":"JM Fletcher","year":"2009","unstructured":"Fletcher JM, Hughes RA (2009) Modified low molecular weight cyclic peptides as mimetics of BDNF with improved potency, proteolytic stability and transmembrane passage in vitro. Bioorg Med Chem 17:2695\u20132702","journal-title":"Bioorg Med Chem"},{"key":"250_CR78","first-page":"168","volume":"41","author":"SE Folstein","year":"1987","unstructured":"Folstein SE, Chase GA, Wahl WE et al (1987) Huntington disease in Maryland: clinical aspects of racial variation. Am J Hum Genet 41:168\u2013179","journal-title":"Am J Hum Genet"},{"key":"250_CR79","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1471-4159.2009.06442.x","volume":"112","author":"CM Forrest","year":"2010","unstructured":"Forrest CM, Mackay GM, Stoy N et al (2010) Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington\u2019s disease. J Neurochem 112:112\u2013122","journal-title":"J Neurochem"},{"key":"250_CR80","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/NDT.S6430","volume":"6","author":"S Frank","year":"2010","unstructured":"Frank S (2010) Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat 6:657\u2013665","journal-title":"Neuropsychiatr Dis Treat"},{"key":"250_CR81","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/WNF.0b013e3180ca77ea","volume":"31","author":"S Frank","year":"2008","unstructured":"Frank S, Ondo W, Fahn S et al (2008) A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 31:127\u2013133","journal-title":"Clin Neuropharmacol"},{"key":"250_CR82","doi-asserted-by":"crossref","first-page":"30715","DOI":"10.1074\/jbc.M709555200","volume":"283","author":"FN Gellerich","year":"2008","unstructured":"Gellerich FN, Gizatullina Z, Nguyen HP et al (2008) Impaired regulation of brain mitochondria by extramitochondrial Ca2\u00a0+\u00a0in transgenic Huntington disease rats. J Biol Chem 283:30715\u201330724","journal-title":"J Biol Chem"},{"issue":"30","key":"250_CR83","doi-asserted-by":"crossref","first-page":"E2772","DOI":"10.1073\/pnas.1303628110","volume":"110","author":"M Gertz","year":"2013","unstructured":"Gertz M, Fischer F, Nguyen GT et al (2013) Ex-527 inhibits Sirtuins by exploiting their unique NAD\u00a0+\u00a0-dependent deacetylation mechanism. Proc Natl Acad Sci U S A 110(30):E2772\u2013781","journal-title":"Proc Natl Acad Sci U S A"},{"key":"250_CR84","doi-asserted-by":"crossref","first-page":"e13417","DOI":"10.1371\/journal.pone.0013417","volume":"5","author":"C Giampa","year":"2010","unstructured":"Giampa C, Laurenti D, Anzilotti S et al (2010) Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington\u2019s disease. PLoS One 5:e13417","journal-title":"PLoS One"},{"key":"250_CR85","doi-asserted-by":"crossref","first-page":"e64037","DOI":"10.1371\/journal.pone.0064037","volume":"8","author":"C Giampa","year":"2013","unstructured":"Giampa C, Montagna E, Dato C et al (2013) Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6\/2 mouse model of Huntington\u2019s disease. PLoS One 8:e64037","journal-title":"PLoS One"},{"key":"250_CR86","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1460-9568.2005.04545.x","volume":"23","author":"C Giamp\u00e0","year":"2006","unstructured":"Giamp\u00e0 C, DeMarch Z, D\u2019Angelo V et al (2006) Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington\u2019s disease. Eur J Neurosci 23:11\u201320","journal-title":"Eur J Neurosci"},{"key":"250_CR87","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.nbd.2009.02.014","volume":"34","author":"C Giamp\u00e0","year":"2009","unstructured":"Giamp\u00e0 C, Patassini S, Borreca A et al (2009a) Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington\u2019s disease. Neurobiol Dis 34:450\u2013456","journal-title":"Neurobiol Dis"},{"key":"250_CR88","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/j.1460-9568.2009.06649.x","volume":"29","author":"C Giamp\u00e0","year":"2009","unstructured":"Giamp\u00e0 C, Middei S, Patassini S et al (2009b) Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6\/2 mouse model of Huntington\u2019s disease. Eur J Neurosci 29:902\u2013910","journal-title":"Eur J Neurosci"},{"key":"250_CR89","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/hmg\/ddg046","volume":"12","author":"S Gines","year":"2003","unstructured":"Gines S (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington\u2019s disease knock-in mice. Hum Mol Genet 12:497\u2013508","journal-title":"Hum Mol Genet"},{"issue":"21","key":"250_CR90","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1093\/hmg\/ddr351","volume":"20","author":"A Giralt","year":"2011","unstructured":"Giralt A, Saavedra A, Carreton O et al (2011) Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington\u2019s disease. Hum Mol Genet 20(21):4232\u20134247","journal-title":"Hum Mol Genet"},{"key":"250_CR91","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1326-6-71","volume":"6","author":"A Giralt","year":"2011","unstructured":"Giralt A, Carreton O, Lao-Peregrin C et al (2011b) Conditional BDNF release under pathological conditions improves Huntington\u2019s disease pathology by delaying neuronal dysfunction. Mol Neurodegener 6:71","journal-title":"Mol Neurodegener"},{"key":"250_CR92","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0306-4522(93)90352-G","volume":"56","author":"M Glass","year":"1993","unstructured":"Glass M, Faull RL, Dragunow M (1993) Loss of cannabinoid receptors in the substantia nigra in Huntington\u2019s disease. Neuroscience 56:523\u2013527","journal-title":"Neuroscience"},{"key":"250_CR93","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","volume":"97","author":"M Glass","year":"2000","unstructured":"Glass M, Dragunow M, Faull RL (2000) The pattern of neurodegeneration in Huntington\u2019s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington\u2019s disease. Neuroscience 97:505\u2013519","journal-title":"Neuroscience"},{"key":"250_CR94","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0006-8993(02)02505-2","volume":"941","author":"J Goggi","year":"2002","unstructured":"Goggi J, Pullar IA, Carney SL et al (2002) Modulation of neurotransmitter release induced by brain-derived neurotrophic factor in rat brain striatal slices in vitro. Brain Res 941:34\u201342","journal-title":"Brain Res"},{"key":"250_CR95","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.expneurol.2012.10.020","volume":"239","author":"MA Gray","year":"2013","unstructured":"Gray MA, Egan GF, Ando A et al (2013) Prefrontal activity in Huntington\u2019s disease reflects cognitive and neuropsychiatric disturbances: the IMAGE-HD study. Exp Neurol 239:218\u2013228","journal-title":"Exp Neurol"},{"key":"250_CR96","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awr333","volume":"135","author":"R Grondin","year":"2012","unstructured":"Grondin R, Kaytor MD, Ai Y et al (2012) Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 135:1197\u20131209","journal-title":"Brain"},{"key":"250_CR97","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.neuron.2005.03.025","volume":"46","author":"X Gu","year":"2005","unstructured":"Gu X, Li C, Wei W et al (2005) Pathological cell\u2013cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46:433\u2013444","journal-title":"Neuron"},{"key":"250_CR98","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1128\/MCB.21.18.6091-6101.2001","volume":"21","author":"MG Guenther","year":"2001","unstructured":"Guenther MG, Barak O, Lazar MA (2001) The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol 21:6091\u20136101","journal-title":"Mol Cell Biol"},{"key":"250_CR99","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0304-3940(00)00956-3","volume":"283","author":"P Guidetti","year":"2000","unstructured":"Guidetti P, Reddy PH, Tagle DA et al (2000) Early kynurenergic impairment in Huntington\u2019s disease and in a transgenic animal model. Neurosci Lett 283:233\u2013235","journal-title":"Neurosci Lett"},{"key":"250_CR100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nbd.2004.07.006","volume":"17","author":"P Guidetti","year":"2004","unstructured":"Guidetti P, Luthi-Carter RE, Augood SJ et al (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington\u2019s disease. Neurobiol Dis 17:455\u2013461","journal-title":"Neurobiol Dis"},{"key":"250_CR101","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2006.02.011","volume":"23","author":"P Guidetti","year":"2006","unstructured":"Guidetti P, Bates GP, Graham RK et al (2006) Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis 23:190\u2013197","journal-title":"Neurobiol Dis"},{"key":"250_CR102","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1172\/JCI64094","volume":"123","author":"JA Hall","year":"2013","unstructured":"Hall JA, Dominy JE, Lee Y et al (2013) The sirtuin family\u2019s role in aging and age-associated pathologies. J Clin Invest 123:973\u2013979","journal-title":"J Clin Invest"},{"key":"250_CR103","doi-asserted-by":"crossref","first-page":"19657","DOI":"10.1074\/jbc.M800595200","volume":"283","author":"N Handa","year":"2008","unstructured":"Handa N, Mizohata E, Kishishita S et al (2008) Crystal Structure of the GAF-B Domain from Human Phosphodiesterase 10A Complexed with Its Ligand, cAMP. J Biol Chem 283:19657\u201319664","journal-title":"J Biol Chem"},{"key":"250_CR104","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/npp.2011.205","volume":"37","author":"E Haroon","year":"2012","unstructured":"Haroon E, Raison CL, Miller AH (2012) Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37:137\u2013162","journal-title":"Neuropsychopharmacology"},{"key":"250_CR105","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s11064-007-9463-1","volume":"33","author":"B Hassel","year":"2008","unstructured":"Hassel B, Tessler S, Faull RL et al (2008) Glutamate uptake is reduced in prefrontal cortex in Huntington\u2019s disease. Neurochem Res 33:232\u2013237","journal-title":"Neurochem Res"},{"key":"250_CR106","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1474-4422(11)70012-6","volume":"10","author":"RA Hauser","year":"2011","unstructured":"Hauser RA, Cantillon M, Pourcher E et al (2011) Preladenant in patients with Parkinson\u2019s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 10:221\u2013229","journal-title":"Lancet Neurol"},{"key":"250_CR107","first-page":"193","volume":"58","author":"MR Hayden","year":"1980","unstructured":"Hayden MR, MacGregor JM, Beighton PH (1980) The prevalence of Huntington\u2019s chorea in South Africa. S Afr Med J 58:193\u2013196","journal-title":"S Afr Med J"},{"key":"250_CR108","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.coph.2006.08.014","volume":"7","author":"A Hebb","year":"2007","unstructured":"Hebb A, Robertson H (2007) Role of phosphodiesterases in neurological and psychiatric disease. Curr Opin Pharmacol 7:86\u201392","journal-title":"Curr Opin Pharmacol"},{"key":"250_CR109","doi-asserted-by":"crossref","unstructured":"Hebb MO, Garcia R, Gaudet P et al (2006) Bilateral stimulation of the globus pallidus internus to treat choreathetosis in Huntington\u2019s disease: technical case report. Neurosurgery 58:E383.discussion E383","DOI":"10.1227\/01.NEU.0000195068.19801.18"},{"key":"250_CR110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/s-2007-1014599","volume":"22","author":"GF Hebenstreit","year":"1989","unstructured":"Hebenstreit GF, Fellerer K, Fichte K et al (1989) Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry 22:156\u2013160","journal-title":"Pharmacopsychiatry"},{"key":"250_CR111","doi-asserted-by":"crossref","first-page":"e50717","DOI":"10.1371\/journal.pone.0050717","volume":"7","author":"T Heikkinen","year":"2012","unstructured":"Heikkinen T, Lehtimaki K, Vartiainen N et al (2012) Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington\u2019s disease. PLoS One 7:e50717","journal-title":"PLoS One"},{"key":"250_CR112","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","volume":"66","author":"SM Hersch","year":"2006","unstructured":"Hersch SM, Gevorkian S, Marder K et al (2006) Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2032dG. Neurology 66:250\u2013252","journal-title":"Neurology"},{"key":"250_CR113","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.mcn.2011.10.007","volume":"49","author":"MA Hickey","year":"2012","unstructured":"Hickey MA, Zhu C, Medvedeva V et al (2012) Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington\u2019s disease. Mol Cell Neurosci 49:149\u2013157","journal-title":"Mol Cell Neurosci"},{"key":"250_CR114","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1093\/hmg\/9.19.2789","volume":"9","author":"P Hilditch-Maguire","year":"2000","unstructured":"Hilditch-Maguire P, Trettel F, Passani LA et al (2000) Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 9:2789\u20132797","journal-title":"Hum Mol Genet"},{"key":"250_CR115","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.expneurol.2010.05.006","volume":"225","author":"DJ Ho","year":"2010","unstructured":"Ho DJ, Calingasan NY, Wille E et al (2010) Resveratrol protects against peripheral deficits in a mouse model of Huntington\u2019s disease. Exp Neurol 225:74\u201384","journal-title":"Exp Neurol"},{"key":"250_CR116","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","volume":"100","author":"E Hockly","year":"2003","unstructured":"Hockly E, Richon VM, Woodman B et al (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease. Proc Natl Acad Sci U S A 100:2041\u20132046","journal-title":"Proc Natl Acad Sci U S A"},{"key":"250_CR117","doi-asserted-by":"crossref","first-page":"e41152","DOI":"10.1371\/journal.pone.0041152","volume":"7","author":"M Hogel","year":"2012","unstructured":"Hogel M, Laprairie RB, Denovan-Wright EM (2012) Promoters are differentially sensitive to N-terminal mutant huntingtin-mediated transcriptional repression. PLoS One 7:e41152","journal-title":"PLoS One"},{"key":"250_CR118","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/ejn.12045","volume":"37","author":"EA Horne","year":"2013","unstructured":"Horne EA, Coy J, Swinney K et al (2013) Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington\u2019s disease and mouse models. Eur J Neurosci 37:429\u2013440","journal-title":"Eur J Neurosci"},{"key":"250_CR119","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1359-6446(05)03622-6","volume":"10","author":"MD Houslay","year":"2005","unstructured":"Houslay MD, Schafer P, Zhang KYJ (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discovery Today 10:1503\u20131519","journal-title":"Drug Discovery Today"},{"key":"250_CR120","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.bcp.2007.03.010","volume":"73","author":"Z Huang","year":"2007","unstructured":"Huang Z, Dias R, Jones T et al (2007) L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. Biochem Pharmacol 73:1971\u20131981","journal-title":"Biochem Pharmacol"},{"issue":"14","key":"250_CR121","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.4161\/cc.25268","volume":"12","author":"BP Hubbard","year":"2013","unstructured":"Hubbard BP, Loh C, Gomes AP et al (2013) Carboxamide SIRT1 inhibitors block DBC1 binding via an acetylation-independent mechanism. Cell Cycle 12(14):2233\u20132240. doi:10.4161\/cc.25268","journal-title":"Cell Cycle"},{"key":"250_CR122","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2174\/1389450111007011237","volume":"11","author":"S Hult","year":"2010","unstructured":"Hult S, Schultz K, Soylu R et al (2010) Hypothalamic and neuroendocrine changes in Huntington\u2019s disease. Curr Drug Targets 11:1237\u20131249","journal-title":"Curr Drug Targets"},{"key":"250_CR123","first-page":"RRN1192","volume":"2","author":"A Hunter","year":"2010","unstructured":"Hunter A, Bordelon Y, Cook I et al. (2010) QEEG measures in Huntington\u2019s disease: a pilot study. PLoS Curr 2:RRN1192","journal-title":"PLoS Curr"},{"key":"250_CR124","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","volume":"57","author":"Huntington Study Group","year":"2001","unstructured":"Huntington Study Group (2001) A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease. Neurology 57:397\u2013404","journal-title":"Neurology"},{"key":"250_CR125","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Huntington Study Group","year":"2006","unstructured":"Huntington Study Group (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66:366\u2013372","journal-title":"Neurology"},{"key":"250_CR126","first-page":"1582","volume":"65","author":"Huntington Study Group TREND-HD Investigators","year":"2008","unstructured":"Huntington Study Group TREND-HD Investigators (2008) Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 65:1582\u20131589","journal-title":"Arch Neurol"},{"key":"250_CR127","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/s-0033-1335097","volume":"81","author":"D Huys","year":"2013","unstructured":"Huys D, Bartsch C, Poppe P et al (2013) Management and outcome of pallidal deep brain stimulation in severe Huntington\u2019s disease. Fortschr Neurol Psychiatr 81:202\u2013205","journal-title":"Fortschr Neurol Psychiatr"},{"key":"250_CR128","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/mds.22408","volume":"25","author":"HC Hyson","year":"2010","unstructured":"Hyson HC, Kieburtz K, Shoulson I et al (2010) Safety and tolerability of high-dosage coenzyme Q10 in Huntington\u2019s disease and healthy subjects. Mov Disord 25:1924\u20131928","journal-title":"Mov Disord"},{"key":"250_CR129","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0014-2999(96)00969-7","volume":"321","author":"T Imanishi","year":"1997","unstructured":"Imanishi T, Sawa A, Ichimaru Y et al (1997) Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. Eur J Pharmacol 321:273\u2013278","journal-title":"Eur J Pharmacol"},{"key":"250_CR130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/mol.53.1.23","volume":"53","author":"S Iona","year":"1998","unstructured":"Iona S, Cuomo M, Bushnik T et al (1998) Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain. Mol Pharmacol 53:23\u201332","journal-title":"Mol Pharmacol"},{"key":"250_CR131","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1523\/JNEUROSCI.19-13-05409.1999","volume":"19","author":"S Ivkovic","year":"1999","unstructured":"Ivkovic S, Ehrlich ME (1999) Expression of the striatal DARPP-32\/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. J Neurosci 19:5409\u20135419","journal-title":"J Neurosci"},{"key":"250_CR132","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1212\/WNL.50.5.1357","volume":"50","author":"BG Jenkins","year":"1998","unstructured":"Jenkins BG, Rosas HD, Chen YC et al (1998) 1H NMR spectroscopy studies of Huntington\u2019s disease: correlations with CAG repeat numbers. Neurology 50:1357\u20131365","journal-title":"Neurology"},{"key":"250_CR133","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00018-005-4533-5","volume":"62","author":"YH Jeon","year":"2005","unstructured":"Jeon YH, Heo YS, Kim CM et al (2005) Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 62:1198\u20131220","journal-title":"Cell Mol Life Sci"},{"key":"250_CR134","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cell.2009.03.018","volume":"137","author":"H Jeong","year":"2009","unstructured":"Jeong H, Then F, Melia TJ Jr et al (2009) Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 137:60\u201372","journal-title":"Cell"},{"key":"250_CR135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.2559","volume":"18","author":"H Jeong","year":"2012","unstructured":"Jeong H, Cohen DE, Cui L et al (2012) Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 18:159\u2013165","journal-title":"Nat Med"},{"key":"250_CR136","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1093\/hmg\/dds379","volume":"21","author":"H Jia","year":"2012","unstructured":"Jia H, Kast RJ, Steffan JS et al (2012a) Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington\u2019s disease mice: implications for the ubiquitin-proteasomal and autophagy systems. Hum Mol Genet 21:5280\u20135293","journal-title":"Hum Mol Genet"},{"key":"250_CR137","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.nbd.2012.01.016","volume":"46","author":"H Jia","year":"2012","unstructured":"Jia H, Pallos J, Jacques V et al (2012b) Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington\u2019s disease. Neurobiol Dis 46:351\u2013361","journal-title":"Neurobiol Dis"},{"key":"250_CR138","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nm.2558","volume":"18","author":"M Jiang","year":"2012","unstructured":"Jiang M, Wang J, Fu J et al (2012) Neuroprotective role of Sirt1 in mammalian models of Huntington\u2019s disease through activation of multiple Sirt1 targets. Nat Med 18:153\u2013158","journal-title":"Nat Med"},{"key":"250_CR139","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1093\/hmg\/ddt098","volume":"22","author":"M Jiang","year":"2013","unstructured":"Jiang M, Peng Q, Liu X et al (2013) Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington\u2019s disease. Hum Mol Genet 22:2462\u20132470","journal-title":"Hum Mol Genet"},{"key":"250_CR140","doi-asserted-by":"crossref","first-page":"12131","DOI":"10.1073\/pnas.1105296108","volume":"108","author":"Y Jiao","year":"2011","unstructured":"Jiao Y, Zhang Z, Zhang C et al (2011) A key mechanism underlying sensory experience-dependent maturation of neocortical GABAergic circuits in vivo. Proc Natl Acad Sci U S A 108:12131\u201312136","journal-title":"Proc Natl Acad Sci U S A"},{"key":"250_CR141","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/jnc.12190","volume":"125","author":"J Jin","year":"2013","unstructured":"Jin J, Albertz J, Guo Z et al (2013) Neuroprotective effects of PPAR-gamma agonist rosiglitazone in N171-82Q mouse model of Huntington\u2019s disease. J Neurochem 125:410\u2013419","journal-title":"J Neurochem"},{"key":"250_CR142","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1196\/annals.1427.036","volume":"1147","author":"JA Johnson","year":"2008","unstructured":"Johnson JA, Johnson DA, Kraft AD et al (2008) The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 1147:61\u201369","journal-title":"Ann N Y Acad Sci"},{"key":"250_CR143","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/hmg\/ddr541","volume":"21","author":"A Johri","year":"2012","unstructured":"Johri A, Calingasan NY, Hennessey TM et al (2012) Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington\u2019s disease. Hum Mol Genet 21:1124\u20131137","journal-title":"Hum Mol Genet"},{"key":"250_CR144","doi-asserted-by":"crossref","first-page":"e54222","DOI":"10.1371\/journal.pone.0054222","volume":"8","author":"A Jovicic","year":"2013","unstructured":"Jovicic A, Zaldivar Jolissaint JF, Moser R et al (2013) MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington\u2019s disease-related mechanisms. PLoS One 8:e54222","journal-title":"PLoS One"},{"key":"250_CR145","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/jnnp.2009.202903","volume":"82","author":"GA Kang","year":"2011","unstructured":"Kang GA, Heath S, Rothlind J et al (2011) Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 82:272\u2013277","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"250_CR146","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1476-5381.2010.01010.x","volume":"161","author":"E Kara","year":"2010","unstructured":"Kara E, Lin H, Svensson K et al (2010) Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor. Br J Pharmacol 161:1343\u20131350","journal-title":"Br J Pharmacol"},{"key":"250_CR147","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/j.1471-4159.2009.06255.x","volume":"110","author":"KB Kegel","year":"2009","unstructured":"Kegel KB, Sapp E, Alexander J et al (2009) Polyglutamine expansion in huntingtin alters its interaction with phospholipids. J Neurochem 110:1585\u20131597","journal-title":"J Neurochem"},{"key":"250_CR148","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ymthe.2004.02.016","volume":"9","author":"AP Kells","year":"2004","unstructured":"Kells AP, Fong DM, Dragunow M et al (2004) AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 9:682\u2013688","journal-title":"Mol Ther"},{"key":"250_CR149","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.nbd.2011.04.015","volume":"43","author":"A Khoshnan","year":"2011","unstructured":"Khoshnan A, Patterson PH (2011) The role of IkappaB kinase complex in the neurobiology of Huntington\u2019s disease. Neurobiol Dis 43:305\u2013311","journal-title":"Neurobiol Dis"},{"key":"250_CR150","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbadis.2010.05.001","volume":"1802","author":"J Kim","year":"2010","unstructured":"Kim J, Amante DJ, Moody JP et al (2010) Reduced creatine kinase as a central and peripheral biomarker in Huntington\u2019s disease. Biochim Biophys Acta 1802:673\u2013681","journal-title":"Biochim Biophys Acta"},{"key":"250_CR151","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1124\/jpet.110.173294","volume":"336","author":"RJ Kleiman","year":"2010","unstructured":"Kleiman RJ, Kimmel LH, Bove SE et al (2010) Chronic suppression of phosphodiesterase 10A alters striatal expression of Genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington\u2019s disease. J Pharmacol Exp Ther 336:64\u201376","journal-title":"J Pharmacol Exp Ther"},{"key":"250_CR152","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1124\/jpet.110.173294","volume":"336","author":"RJ Kleiman","year":"2011","unstructured":"Kleiman RJ, Kimmel LH, Bove SE et al (2011) Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington\u2019s disease. J Pharmacol Exp Ther 336:64\u201376","journal-title":"J Pharmacol Exp Ther"},{"key":"250_CR153","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.intimp.2011.01.023","volume":"11","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Kubo S, Iwata M et al (2011) ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity. Int Immunopharmacol 11:732\u2013739","journal-title":"Int Immunopharmacol"},{"key":"250_CR154","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.neuroscience.2010.05.052","volume":"169","author":"A Konradsson-Geuken","year":"2010","unstructured":"Konradsson-Geuken A, Wu HQ, Gash CR et al (2010) Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry. Neuroscience 169:1848\u20131859","journal-title":"Neuroscience"},{"key":"250_CR155","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB, Stanek LM, Wancewicz EV et al (2012) Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron 74:1031\u20131044","journal-title":"Neuron"},{"key":"250_CR156","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1074\/jbc.M308471200","volume":"279","author":"J Kotera","year":"2003","unstructured":"Kotera J (2003) Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMP-dependent protein kinase-dependent phosphorylation. J Biol Chem 279:4366\u20134375","journal-title":"J Biol Chem"},{"issue":"8","key":"250_CR157","first-page":"1101","volume":"25","author":"M Kuroiwa","year":"2011","unstructured":"Kuroiwa M, Snyder GL, Shuto T et al (2011) Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor\/PKA\/DARPP-32 signaling cascade in frontal cortex. Psychopharmacology (Berl) 25(8):1101\u20131117","journal-title":"Psychopharmacology (Berl)"},{"key":"250_CR158","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nm.2624","volume":"18","author":"AR La Spada","year":"2012","unstructured":"La Spada AR (2012) Finding a sirtuin truth in Huntington\u2019s disease. Nat Med 18:24\u201326","journal-title":"Nat Med"},{"key":"250_CR159","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","volume":"62","author":"GB Landwehrmeyer","year":"2007","unstructured":"Landwehrmeyer GB, Dubois B, de Yebenes JG et al (2007) Riluzole in Huntington\u2019s disease: a 3-year, randomized controlled study. Ann Neurol 62:262\u2013272","journal-title":"Ann Neurol"},{"key":"250_CR160","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajmg.b.30992","volume":"153B","author":"DR Langbehn","year":"2010","unstructured":"Langbehn DR, Hayden MR, Paulsen JS (2010) CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 153B:397\u2013408","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"250_CR161","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0006-8993(01)03403-5","volume":"929","author":"I Lastres-Becker","year":"2002","unstructured":"Lastres-Becker I, Berrendero F, Lucas JJ et al (2002) Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington\u2019s disease. Brain Res 929:236\u2013242","journal-title":"Brain Res"},{"key":"250_CR162","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1152\/jn.00472.2010","volume":"104","author":"F Lemtiri-Chlieh","year":"2010","unstructured":"Lemtiri-Chlieh F, Levine ES (2010) BDNF evokes release of endogenous cannabinoids at layer 2\/3 inhibitory synapses in the neocortex. J Neurophysiol 104:1923\u20131932","journal-title":"J Neurophysiol"},{"key":"250_CR163","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1523\/JNEUROSCI.5236-10.2011","volume":"31","author":"YF Li","year":"2011","unstructured":"Li YF, Cheng YF, Huang Y et al (2011) Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. J Neurosci 31:172\u2013183","journal-title":"J Neurosci"},{"key":"250_CR164","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/jcbfm.2010.186","volume":"31","author":"N Ligot","year":"2011","unstructured":"Ligot N, Krystkowiak P, Simonin C et al (2011) External globus pallidus stimulation modulates brain connectivity in Huntington\u2019s disease. J Cereb Blood Flow Metab 31:41\u201346","journal-title":"J Cereb Blood Flow Metab"},{"key":"250_CR165","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1172\/JCI43220","volume":"121","author":"YS Lin","year":"2011","unstructured":"Lin YS, Chen CM, Soong BW et al (2011) Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease. J Clin Invest 121:1519\u20131523","journal-title":"J Clin Invest"},{"key":"250_CR166","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1523\/JNEUROSCI.2033-12.2013","volume":"33","author":"G Liot","year":"2013","unstructured":"Liot G, Zala D, Pla P et al (2013) Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J Neurosci 33:6298\u20136309","journal-title":"J Neurosci"},{"key":"250_CR167","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1124\/jpet.107.123109","volume":"322","author":"C Lopes","year":"2007","unstructured":"Lopes C, Pereira EF, Wu HQ et al (2007) Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors. J Pharmacol Exp Ther 322:48\u201358","journal-title":"J Pharmacol Exp Ther"},{"key":"250_CR168","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/WNF.0b013e3181ebb285","volume":"33","author":"A Lundin","year":"2010","unstructured":"Lundin A, Dietrichs E, Haghighi S et al (2010) Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington\u2019s disease. Clin Neuropharmacol 33:260\u2013264","journal-title":"Clin Neuropharmacol"},{"key":"250_CR169","doi-asserted-by":"crossref","first-page":"7927","DOI":"10.1073\/pnas.1002924107","volume":"107","author":"R Luthi-Carter","year":"2010","unstructured":"Luthi-Carter R, Taylor DM, Pallos J et al (2010) SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci U S A 107:7927\u20137932","journal-title":"Proc Natl Acad Sci U S A"},{"key":"250_CR170","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1471-4914(01)02179-7","volume":"7","author":"RL Margolis","year":"2001","unstructured":"Margolis RL, Ross CA (2001) Expansion explosion: new clues to the pathogenesis of repeat expansion neurodegenerative diseases. Trends Mol Med 7:479\u2013482","journal-title":"Trends Mol Med"},{"key":"250_CR171","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2013.03.044","volume":"709","author":"D Marongiu","year":"2013","unstructured":"Marongiu D, Imbrosci B, Mittmann T (2013) Modulatory effects of the novel TrkB receptor agonist 7,8-dihydroxyflavone on synaptic transmission and intrinsic neuronal excitability in mouse visual cortex in vitro. Eur J Pharmacol 709:64\u201371","journal-title":"Eur J Pharmacol"},{"key":"250_CR172","doi-asserted-by":"crossref","first-page":"8772","DOI":"10.1523\/JNEUROSCI.21-22-08772.2001","volume":"21","author":"E Martin-Aparicio","year":"2001","unstructured":"Martin-Aparicio E, Yamamoto A, Hernandez F et al (2001) Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington\u2019s disease. J Neurosci 21:8772\u20138781","journal-title":"J Neurosci"},{"key":"250_CR173","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.nbd.2009.09.012","volume":"37","author":"A Martire","year":"2010","unstructured":"Martire A, Ferrante A, Potenza RL et al (2010) Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington\u2019s disease mice. Neurobiol Dis 37:99\u2013105","journal-title":"Neurobiol Dis"},{"key":"250_CR174","doi-asserted-by":"publisher","unstructured":"Martire A, Pepponi R, Domenici MR et al (2013) BDNF prevents NMDA-induced toxicity in models of Huntington\u2019s disease: the effects are genotype specific and adenosine A(2A) receptor is involved. J Neurochem doi:10.1111\/jnc.12177","DOI":"10.1111\/jnc.12177"},{"key":"250_CR175","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1172\/JCI41356","volume":"120","author":"SM Massa","year":"2010","unstructured":"Massa SM, Yang T, Xie Y et al (2010) Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest 120:1774\u20131785","journal-title":"J Clin Invest"},{"key":"250_CR176","doi-asserted-by":"crossref","unstructured":"Mazarei G, Budac DP, Lu G et al (2013) Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. J Neurochem doi: 10.1111\/jnc.12350","DOI":"10.1111\/jnc.12350"},{"key":"250_CR177","doi-asserted-by":"crossref","first-page":"e41423","DOI":"10.1371\/journal.pone.0041423","volume":"7","author":"KN McFarland","year":"2012","unstructured":"McFarland KN, Das S, Sun TT et al (2012) Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington\u2019s disease. PLoS One 7:e41423","journal-title":"PLoS One"},{"key":"250_CR178","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0090-9556(25)06690-5","volume":"15","author":"R Mehvar","year":"1987","unstructured":"Mehvar R, Jamali F, Watson MW et al (1987) Pharmacokinetics of tetrabenazine and its major metabolite in man and rat: Bioavailability and dose dependency studies. Drug Metab Dispos 15:250\u2013255","journal-title":"Drug Metab Dispos"},{"key":"250_CR179","doi-asserted-by":"crossref","first-page":"e9793","DOI":"10.1371\/journal.pone.0009793","volume":"5","author":"LB Menalled","year":"2010","unstructured":"Menalled LB, Patry M, Ragland N et al (2010) Comprehensive behavioral testing in the R6\/2 mouse model of Huntington\u2019s disease shows no benefit from CoQ10 or minocycline. PLoS One 5:e9793","journal-title":"PLoS One"},{"key":"250_CR180","doi-asserted-by":"crossref","first-page":"e27746","DOI":"10.1371\/journal.pone.0027746","volume":"6","author":"M Mielcarek","year":"2011","unstructured":"Mielcarek M, Benn CL, Franklin SA et al (2011) SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6\/2 mouse model of Huntington\u2019s disease. PLoS One 6:e27746","journal-title":"PLoS One"},{"key":"250_CR181","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.nbd.2011.03.006","volume":"42","author":"S Mievis","year":"2011","unstructured":"Mievis S, Blum D, Ledent C (2011) Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol Dis 42:524\u2013529","journal-title":"Neurobiol Dis"},{"key":"250_CR182","doi-asserted-by":"crossref","unstructured":"Miller JP, Hughes RE (2011) Protein interactions and target discovery in Huntington\u2019s disease. In: Lo DC, Hughes RE (eds) Neurobiology of Huntington\u2019s disease. Applications to drug discovery. CRC, Boca Raton","DOI":"10.1201\/EBK0849390005-c3"},{"key":"250_CR183","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1471-4159.2012.07691.x","volume":"121","author":"BR Miller","year":"2012","unstructured":"Miller BR, Dorner JL, Bunner KD et al (2012) Up-regulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6\/2 mouse model of Huntington\u2019s disease. J Neurochem 121:629\u2013638","journal-title":"J Neurochem"},{"key":"250_CR184","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.nbd.2012.05.013","volume":"48","author":"AJ Milnerwood","year":"2012","unstructured":"Milnerwood AJ, Kaufman AM, Sepers MD et al (2012) Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington\u2019s disease mice. Neurobiol Dis 48:40\u201351","journal-title":"Neurobiol Dis"},{"key":"250_CR185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmb.2012.09.011","volume":"424","author":"R Mishra","year":"2012","unstructured":"Mishra R, Hoop CL, Kodali R et al (2012) Serine phosphorylation suppresses huntingtin amyloid accumulation by altering protein aggregation properties. J Mol Biol 424:1\u201314","journal-title":"J Mol Biol"},{"key":"250_CR186","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1016\/j.bmcl.2010.07.136","volume":"20","author":"CJ Mitchell","year":"2010","unstructured":"Mitchell CJ, Ballantine SP, Coe DM et al (2010) Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR. Bioorg Med Chem Lett 20:5803\u20135806","journal-title":"Bioorg Med Chem Lett"},{"key":"250_CR187","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.biopsych.2010.12.023","volume":"69","author":"N Miyake","year":"2011","unstructured":"Miyake N, Skinbjerg M, Easwaramoorthy B et al (2011) Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer [11C] ABP688 and N-acetylcysteine challenge. Biol Psychiatry 69:822\u2013824","journal-title":"Biol Psychiatry"},{"key":"250_CR188","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/mds.23107","volume":"25","author":"Y Mizuno","year":"2010","unstructured":"Mizuno Y, Hasegawa K, Kondo T et al (2010) Clinical efficacy of istradefylline (KW-6002) in Parkinson\u2019s disease: a randomized, controlled study. Mov Disord 25:1437\u20131443","journal-title":"Mov Disord"},{"key":"250_CR189","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1172\/JCI45691","volume":"121","author":"F Mochel","year":"2011","unstructured":"Mochel F, Haller RG (2011) Energy deficit in Huntington disease: why it matters. J Clin Invest 121:493\u2013499","journal-title":"J Clin Invest"},{"key":"250_CR190","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ejhg.2010.72","volume":"18","author":"F Mochel","year":"2010","unstructured":"Mochel F, Duteil S, Marelli C et al (2010) Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington\u2019s disease. Eur J Hum Genet 18:1057\u20131060","journal-title":"Eur J Hum Genet"},{"key":"250_CR191","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1074\/jbc.M111.309849","volume":"287","author":"F Mochel","year":"2012","unstructured":"Mochel F, Durant B, Meng X et al (2012) Early alterations of brain cellular energy homeostasis in Huntington disease models. J Biol Chem 287:1361\u20131370","journal-title":"J Biol Chem"},{"key":"250_CR192","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neuropharm.2009.06.003","volume":"57","author":"MH Mok","year":"2009","unstructured":"Mok MH, Fricker AC, Weil A et al (2009) Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels. Neuropharmacology 57:242\u2013249","journal-title":"Neuropharmacology"},{"key":"250_CR193","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.20183","volume":"56","author":"E Moro","year":"2004","unstructured":"Moro E, Lang AE, Strafella AP et al (2004) Bilateral globus pallidus stimulation for Huntington\u2019s disease. Ann Neurol 56:290\u2013294","journal-title":"Ann Neurol"},{"key":"250_CR194","doi-asserted-by":"crossref","first-page":"e31080","DOI":"10.1371\/journal.pone.0031080","volume":"7","author":"L Moumne","year":"2012","unstructured":"Moumne L, Campbell K, Howland D et al (2012) Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington\u2019s disease. PLoS One 7:e31080","journal-title":"PLoS One"},{"key":"250_CR195","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1172\/JCI45364","volume":"121","author":"I Munoz-Sanjuan","year":"2011","unstructured":"Munoz-Sanjuan I, Bates GP (2011) The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J Clin Invest 121:476\u2013483","journal-title":"J Clin Invest"},{"key":"250_CR196","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/sj.bjp.0704629","volume":"135","author":"A Nagakura","year":"2002","unstructured":"Nagakura A, Niimura M, Takeo S (2002) Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats. Br J Pharmacol 135:1783\u20131793","journal-title":"Br J Pharmacol"},{"key":"250_CR197","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1016\/j.bmcl.2009.04.121","volume":"19","author":"K Naganuma","year":"2009","unstructured":"Naganuma K, Omura A, Maekawara N et al (2009) Discovery of selective PDE4B inhibitors. Bioorg Med Chem Lett 19:3174\u20133176","journal-title":"Bioorg Med Chem Lett"},{"key":"250_CR198","doi-asserted-by":"crossref","first-page":"23489","DOI":"10.1074\/jbc.M112.365874","volume":"287","author":"V Nin","year":"2012","unstructured":"Nin V, Escande C, Chini CC et al (2012) Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase. J Biol Chem 287:23489\u201323501","journal-title":"J Biol Chem"},{"key":"250_CR199","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1073\/pnas.0409138102","volume":"102","author":"A Nishi","year":"2005","unstructured":"Nishi A, Watanabe Y, Higashi H et al (2005) Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc Natl Acad Sci U S A 102:1199\u20131204","journal-title":"Proc Natl Acad Sci U S A"},{"key":"250_CR200","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1523\/JNEUROSCI.3493-03.2004","volume":"24","author":"K Obrietan","year":"2004","unstructured":"Obrietan K (2004) CRE-mediated transcription is increased in Huntington\u2019s disease transgenic mice. J Neurosci 24:791\u2013796","journal-title":"J Neurosci"},{"key":"250_CR201","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1471-4159.1998.70010299.x","volume":"70","author":"S Okuda","year":"1998","unstructured":"Okuda S, Nishiyama N, Saito H et al (1998) 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 70:299\u2013307","journal-title":"J Neurochem"},{"key":"250_CR202","doi-asserted-by":"crossref","first-page":"25738","DOI":"10.1074\/jbc.M303209200","volume":"278","author":"PD O\u2019Leary","year":"2003","unstructured":"O\u2019Leary PD, Hughes RA (2003) Design of potent peptide mimetics of brain-derived neurotrophic factor. J Biol Chem 278:25738\u201325744","journal-title":"J Biol Chem"},{"key":"250_CR203","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.expneurol.2011.08.005","volume":"232","author":"M Orru","year":"2011","unstructured":"Orru M, Zanoveli JM, Quiroz C et al (2011a) Functional changes in postsynaptic adenosine A(2A) receptors during early stages of a rat model of Huntington disease. Exp Neurol 232:76\u201380","journal-title":"Exp Neurol"},{"key":"250_CR204","doi-asserted-by":"crossref","first-page":"e16088","DOI":"10.1371\/journal.pone.0016088","volume":"6","author":"M Orru","year":"2011","unstructured":"Orru M, Bakesova J, Brugarolas M et al (2011b) Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonists. PLoS One 6:e16088","journal-title":"PLoS One"},{"key":"250_CR205","first-page":"545","volume":"3","author":"D Paleacu","year":"2007","unstructured":"Paleacu D (2007) Tetrabenazine in the treatment of Huntington\u2019s disease. Neuropsychiatr Dis Treat 3:545\u2013551","journal-title":"Neuropsychiatr Dis Treat"},{"key":"250_CR206","doi-asserted-by":"crossref","first-page":"e62616","DOI":"10.1371\/journal.pone.0062616","volume":"8","author":"M Perreault","year":"2013","unstructured":"Perreault M, Feng G, Will S et al (2013) Activation of TrkB with TAM-163 results in opposite effects on body weight in rodents and non-human primates. PLoS One 8:e62616","journal-title":"PLoS One"},{"key":"250_CR207","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0014-2999(84)90562-4","volume":"102","author":"DJ Pettibone","year":"1984","unstructured":"Pettibone DJ, Totaro JA, Pflueger AB (1984a) Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol 102:425\u2013430","journal-title":"Eur J Pharmacol"},{"key":"250_CR208","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0014-2999(84)90563-6","volume":"102","author":"DJ Pettibone","year":"1984","unstructured":"Pettibone DJ, Pflueger AB, Totaro JA (1984b) Tetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepinephrine. Eur J Pharmacol 102:431\u2013436","journal-title":"Eur J Pharmacol"},{"key":"250_CR209","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tins.2007.07.008","volume":"30","author":"A Pisani","year":"2007","unstructured":"Pisani A, Bernardi G, Ding J et al (2007) Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci 30:545\u2013553","journal-title":"Trends Neurosci"},{"key":"250_CR210","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/npp.2011.127","volume":"36","author":"A Pocivavsek","year":"2011","unstructured":"Pocivavsek A, Wu HQ, Potter MC et al (2011) Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology 36:2357\u20132367","journal-title":"Neuropsychopharmacology"},{"key":"250_CR211","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2010.07.023","volume":"644","author":"H Ponten","year":"2010","unstructured":"Ponten H, Kullingsjo J, Lagerkvist S et al (2010) In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol 644:88\u201395","journal-title":"Eur J Pharmacol"},{"key":"250_CR212","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2174\/138161208784480117","volume":"14","author":"P Popoli","year":"2008","unstructured":"Popoli P, Blum D, Domenici MR et al (2008) A critical evaluation of adenosine A2A receptors as potentially druggable targets in Huntington\u2019s disease. Curr Pharm Des 14:1500\u20131511","journal-title":"Curr Pharm Des"},{"key":"250_CR213","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00001756-200201210-00029","volume":"13","author":"BK Puri","year":"2002","unstructured":"Puri BK, Bydder GM, Counsell SJ et al (2002) MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 13:123\u2013126","journal-title":"Neuroreport"},{"key":"250_CR214","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/01.wnl.0000169025.09670.6d","volume":"65","author":"BK Puri","year":"2005","unstructured":"Puri BK, Leavitt BR, Hayden MR et al (2005) Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 65:286\u2013292","journal-title":"Neurology"},{"key":"250_CR215","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1523\/JNEUROSCI.1409-03.2004","volume":"24","author":"ZH Qin","year":"2004","unstructured":"Qin ZH, Wang Y, Sapp E et al (2004) Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci 24:269\u2013281","journal-title":"J Neurosci"},{"key":"250_CR216","doi-asserted-by":"crossref","unstructured":"Quinti L, Chopra V, Rotili D et al (2010) Evaluation of histone deacetylases as drug targets in Huntington\u2019s disease models: study of HDACs in brain tissues from R6\/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model. PLoS Curr 2: pii:RRN1172","DOI":"10.1371\/currents.RRN1172"},{"key":"250_CR217","doi-asserted-by":"crossref","first-page":"e54364","DOI":"10.1371\/journal.pone.0054364","volume":"8","author":"R Raynes","year":"2013","unstructured":"Raynes R, Pombier KM, Nguyen K et al (2013) The SIRT1 modulators AROS and DBC1 regulate HSF1 activity and the heat shock response. PLoS One 8:e54364","journal-title":"PLoS One"},{"key":"250_CR218","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1385\/MN:28:3:259","volume":"28","author":"A Reiner","year":"2003","unstructured":"Reiner A, Dragatsis I, Zeitlin S et al (2003) Wild-type huntingtin plays a role in brain development and neuronal survival. Mol Neurobiol 28:259\u2013276","journal-title":"Mol Neurobiol"},{"key":"250_CR219","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.nbd.2012.03.025","volume":"47","author":"A Reiner","year":"2012","unstructured":"Reiner A, Lafferty DC, Wang HB et al (2012) The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6\/2 Huntington\u2019s disease mice. Neurobiol Dis 47:75\u201391","journal-title":"Neurobiol Dis"},{"key":"250_CR220","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/mds.22245","volume":"23","author":"NC Reynolds","year":"2008","unstructured":"Reynolds NC, Prost RW, Mark LP et al (2008) MR-spectroscopic findings in juvenile-onset Huntington\u2019s disease. Mov Disord 23:1931\u20131935","journal-title":"Mov Disord"},{"key":"250_CR221","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1523\/JNEUROSCI.4974-09.2010","volume":"30","author":"FM Ribeiro","year":"2010","unstructured":"Ribeiro FM, Paquet M, Ferreira LT et al (2010) Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington\u2019s disease. J Neurosci 30:316\u2013324","journal-title":"J Neurosci"},{"key":"250_CR222","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ana.410360406","volume":"36","author":"EK Richfield","year":"1994","unstructured":"Richfield EK, Herkenham M (1994) Selective vulnerability in Huntington\u2019s disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 36:577\u2013584","journal-title":"Ann Neurol"},{"key":"250_CR223","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/BF00615962","volume":"29","author":"MS Roberts","year":"1986","unstructured":"Roberts MS, McLean S, Millingen KS et al (1986) The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. Eur J Clin Pharmacol 29:703\u2013708","journal-title":"Eur J Clin Pharmacol"},{"key":"250_CR224","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0028-3908(98)00190-7","volume":"38","author":"A Robichaud","year":"1999","unstructured":"Robichaud A, Tattersall FD, Choudhury I et al (1999) Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology 38:289\u2013297","journal-title":"Neuropharmacology"},{"key":"250_CR225","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.bjp.0704457","volume":"135","author":"A Robichaud","year":"2002","unstructured":"Robichaud A, Savoie C, Stamatiou PB et al (2002) Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol 135:113\u2013118","journal-title":"Br J Pharmacol"},{"issue":"3","key":"250_CR226","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.neuropharm.2011.08.008","volume":"62","author":"JS Rodefer","year":"2012","unstructured":"Rodefer JS, Saland SK, Eckrich SJ (2012) Selective phosphodiesterase inhibitors improve performance on the ED\/ID cognitive task in rats. Neuropharmacology 62(3):1182-1190","journal-title":"Neuropharmacology"},{"key":"250_CR227","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.2174\/138161205774370799","volume":"11","author":"GM Rose","year":"2005","unstructured":"Rose GM, Hopper A, De Vivo M et al (2005) Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des 11:3329\u20133334","journal-title":"Curr Pharm Des"},{"key":"250_CR228","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ (2011) Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10:83\u201398","journal-title":"Lancet Neurol"},{"key":"250_CR229","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00702-008-0038-3","volume":"115","author":"JP Rung","year":"2008","unstructured":"Rung JP, Rung E, Helgeson L et al (2008) Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J Neural Transm 115:899\u2013908","journal-title":"J Neural Transm"},{"key":"250_CR230","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.nlm.2005.09.002","volume":"85","author":"K Rutten","year":"2006","unstructured":"Rutten K, Prickaerts J, Blokland A (2006) Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiol Learn Mem 85:132\u2013138","journal-title":"Neurobiol Learn Mem"},{"key":"250_CR231","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00213-006-0697-4","volume":"192","author":"K Rutten","year":"2007","unstructured":"Rutten K, Lieben C, Smits L et al (2007a) The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat. Psychopharmacology (Berl) 192:275\u2013282","journal-title":"Psychopharmacology (Berl)"},{"key":"250_CR232","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2006.11.041","volume":"558","author":"K Rutten","year":"2007","unstructured":"Rutten K, Prickaerts J, Hendrix M et al (2007b) Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur J Pharmacol 558:107\u2013112","journal-title":"Eur J Pharmacol"},{"key":"250_CR233","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00213-007-0999-1","volume":"196","author":"K Rutten","year":"2008","unstructured":"Rutten K, Basile JL, Prickaerts J et al (2008) Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology (Berl) 196:643\u2013648","journal-title":"Psychopharmacology (Berl)"},{"key":"250_CR234","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/hmg\/ddm078","volume":"16","author":"G Sadri-Vakili","year":"2007","unstructured":"Sadri-Vakili G, Bouzou B, Benn CL et al (2007) Histones associated with downregulated genes are hypo-acetylated in Huntington\u2019s disease models. Hum Mol Genet 16:1293\u20131306","journal-title":"Hum Mol Genet"},{"key":"250_CR235","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1172\/JCI45130","volume":"121","author":"DW Sah","year":"2011","unstructured":"Sah DW, Aronin N (2011) Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest 121:500\u2013507","journal-title":"J Clin Invest"},{"key":"250_CR236","doi-asserted-by":"crossref","first-page":"407","DOI":"10.5694\/j.1326-5377.1981.tb135681.x","volume":"1","author":"PR Sanberg","year":"1981","unstructured":"Sanberg PR, Fibiger HC, Mark RF (1981) Body weight and dietary factors in Huntington\u2019s disease patients compared with matched controls. Med J Aust 1:407\u2013409","journal-title":"Med J Aust"},{"key":"250_CR237","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.expneurol.2005.07.004","volume":"197","author":"MT Sapko","year":"2006","unstructured":"Sapko MT, Guidetti P, Yu P et al (2006) Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington\u2019s disease. Exp Neurol 197:31\u201340","journal-title":"Exp Neurol"},{"key":"250_CR238","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1423-0127-17-62","volume":"17","author":"Y Sari","year":"2010","unstructured":"Sari Y, Prieto AL, Barton SJ et al (2010) Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6\/2 model of Huntington\u2019s disease. J Biomed Sci 17:62","journal-title":"J Biomed Sci"},{"key":"250_CR239","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/hmg\/ddp467","volume":"19","author":"K Sathasivam","year":"2010","unstructured":"Sathasivam K, Lane A, Legleiter J et al (2010) Identical oligomeric and fibrillar structures captured from the brains of R6\/2 and knock-in mouse models of Huntington\u2019s disease. Hum Mol Genet 19:65\u201378","journal-title":"Hum Mol Genet"},{"key":"250_CR240","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","volume":"110","author":"K Sathasivam","year":"2013","unstructured":"Sathasivam K, Neueder A, Gipson TA et al (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A 110:2366\u20132370","journal-title":"Proc Natl Acad Sci U S A"},{"key":"250_CR241","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1471-4159.2010.06675.x","volume":"113","author":"KV Sathyasaikumar","year":"2010","unstructured":"Sathyasaikumar KV, Stachowski EK, Amori L et al (2010) Dysfunctional kynurenine pathway metabolism in the R6\/2 mouse model of Huntington\u2019s disease. J Neurochem 113:1416\u20131425","journal-title":"J Neurochem"},{"key":"250_CR242","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.brainres.2004.06.005","volume":"1019","author":"J Schiefer","year":"2004","unstructured":"Schiefer J, Sprunken A, Puls C et al (2004) The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington\u2019s disease. Brain Res 1019:246\u2013254","journal-title":"Brain Res"},{"key":"250_CR243","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","volume":"325","author":"CJ Schmidt","year":"2008","unstructured":"Schmidt CJ, Chapin DS, Cianfrogna J et al (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:681\u2013690","journal-title":"J Pharmacol Exp Ther"},{"key":"250_CR244","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrn3257","volume":"13","author":"R Schwarcz","year":"2012","unstructured":"Schwarcz R, Bruno JP, Muchowski PJ et al (2012) Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13:465\u2013477","journal-title":"Nat Rev Neurosci"},{"key":"250_CR245","doi-asserted-by":"crossref","first-page":"42444","DOI":"10.1074\/jbc.R112.402768","volume":"287","author":"C Sebastian","year":"2012","unstructured":"Sebastian C, Satterstrom FK, Haigis MC et al (2012) From sirtuin biology to human diseases: an update. J Biol Chem 287:42444\u201342452","journal-title":"J Biol Chem"},{"key":"250_CR246","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","volume":"985","author":"T Seeger","year":"2003","unstructured":"Seeger T (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113\u2013126","journal-title":"Brain Res"},{"key":"250_CR247","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1093\/hmg\/ddi319","volume":"14","author":"IS Seong","year":"2005","unstructured":"Seong IS, Ivanova E, Lee JM et al (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 14:2871\u20132880","journal-title":"Hum Mol Genet"},{"key":"250_CR248","doi-asserted-by":"crossref","first-page":"e64953","DOI":"10.1371\/journal.pone.0064953","volume":"8","author":"BH Shin","year":"2013","unstructured":"Shin BH, Lim Y, Oh HJ et al (2013) Pharmacological activation of Sirt1 Ameliorates Polyglutamine-induced toxicity through the regulation of autophagy. PLoS One 8:e64953","journal-title":"PLoS One"},{"key":"250_CR249","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuron.2012.05.024","volume":"75","author":"DI Shirasaki","year":"2012","unstructured":"Shirasaki DI, Greiner ER, Al-Ramahi I et al (2012) Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron 75:41\u201357","journal-title":"Neuron"},{"key":"250_CR250","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1098\/rstb.2012.0313","volume":"367","author":"SD Skaper","year":"2012","unstructured":"Skaper SD, Di Marzo V (2012) Endocannabinoids in nervous system health and disease: the big picture in a nutshell. Philos Trans R Soc Lond B Biol Sci 367:3193\u20133200","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"250_CR251","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1471-4159.2010.07122.x","volume":"116","author":"C Soldati","year":"2011","unstructured":"Soldati C, Bithell A, Conforti P et al (2011) Rescue of gene expression by modified REST decoy oligonucleotides in a cellular model of Huntington\u2019s disease. J Neurochem 116:415\u2013425","journal-title":"J Neurochem"},{"key":"250_CR252","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1471-4159.2009.06004.x","volume":"109","author":"F Sotty","year":"2009","unstructured":"Sotty F, Montezinho LP, Steiniger-Brach B et al (2009) Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to d-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons. J Neurochem 109:766\u2013775","journal-title":"J Neurochem"},{"key":"250_CR253","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/bjp.2008.307","volume":"155","author":"D Spina","year":"2008","unstructured":"Spina D (2008) PDE4 inhibitors: current status. Br J Pharmacol 155:308\u2013315","journal-title":"Br J Pharmacol"},{"key":"250_CR254","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1212\/WNL.0b013e3182886965","volume":"80","author":"F Squitieri","year":"2013","unstructured":"Squitieri F, Landwehrmeyer B, Reilmann R et al (2013) One-year safety and tolerability profile of pridopidine in patients with Huntington disease. Neurology 80:1086\u20131094","journal-title":"Neurology"},{"key":"250_CR255","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","volume":"413","author":"JS Steffan","year":"2001","unstructured":"Steffan JS, Bodai L, Pallos J et al (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739\u2013743","journal-title":"Nature"},{"key":"250_CR256","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.expneurol.2011.11.020","volume":"233","author":"DK Stiles","year":"2012","unstructured":"Stiles DK, Zhang Z, Ge P et al (2012) Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol 233:463\u2013471","journal-title":"Exp Neurol"},{"key":"250_CR257","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrd870","volume":"1","author":"TW Stone","year":"2002","unstructured":"Stone TW, Darlington LG (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1:609\u2013620","journal-title":"Nat Rev Drug Discov"},{"key":"250_CR258","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1074\/jbc.M310226200","volume":"279","author":"KL Sugars","year":"2003","unstructured":"Sugars KL (2003) Decreased cAMP Response Element-mediated Transcription: an early event in exon 1 and full-length cell models of Huntington\u2019s disease that contributes to polyglutamine pathogenesis. J Biol Chem 279:4988\u20134999","journal-title":"J Biol Chem"},{"key":"250_CR259","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s12035-012-8316-3","volume":"46","author":"PM Switonski","year":"2012","unstructured":"Switonski PM, Szlachcic WJ, Gabka A et al (2012) Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. Mol Neurobiol 46:430\u2013466","journal-title":"Part II. Mol Neurobiol"},{"key":"250_CR260","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1212\/01.WNL.0000070186.97463.A7","volume":"61","author":"SJ Tabrizi","year":"2003","unstructured":"Tabrizi SJ, Blamire AM, Manners DN et al (2003) Creatine therapy for Huntington\u2019s disease: clinical and MRS findings in a 1-year pilot study. Neurology 61:141\u2013142","journal-title":"Neurology"},{"key":"250_CR261","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nsmb.1700","volume":"16","author":"S Tam","year":"2009","unstructured":"Tam S, Spiess C, Auyeung W et al (2009) The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat Struct Mol Biol 16:1279\u20131285","journal-title":"Nat Struct Mol Biol"},{"key":"250_CR262","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00221-005-2359-x","volume":"166","author":"JK Tang","year":"2005","unstructured":"Tang JK, Moro E, Lozano AM et al (2005) Firing rates of pallidal neurons are similar in Huntington\u2019s and Parkinson\u2019s disease patients. Exp Brain Res 166:230\u2013236","journal-title":"Exp Brain Res"},{"key":"250_CR263","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nbd.2011.02.008","volume":"42","author":"B Tang","year":"2011","unstructured":"Tang B, Seredenina T, Coppola G et al (2011) Gene expression profiling of R6\/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington\u2019s disease. Neurobiol Dis 42:459\u2013467","journal-title":"Neurobiol Dis"},{"key":"250_CR264","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.nbd.2006.01.014","volume":"23","author":"A Tarditi","year":"2006","unstructured":"Tarditi A, Camurri A, Varani K et al (2006) Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol Dis 23:44\u201353","journal-title":"Neurobiol Dis"},{"key":"250_CR265","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neulet.2006.07.036","volume":"406","author":"Y Temel","year":"2006","unstructured":"Temel Y, Cao C, Vlamings R et al (2006) Motor and cognitive improvement by deep brain stimulation in a transgenic rat model of Huntington\u2019s disease. Neurosci Lett 406:138\u2013141","journal-title":"Neurosci Lett"},{"key":"250_CR266","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nsmb.1570","volume":"16","author":"AK Thakur","year":"2009","unstructured":"Thakur AK, Jayaraman M, Mishra R et al (2009) Polyglutamine disruption of the huntingtin exon 1\u00a0N terminus triggers a complex aggregation mechanism. Nat Struct Mol Biol 16:380\u2013389","journal-title":"Nat Struct Mol Biol"},{"key":"250_CR267","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72:971\u2013983","journal-title":"Cell"},{"key":"250_CR268","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","volume":"105","author":"EA Thomas","year":"2008","unstructured":"Thomas EA, Coppola G, Desplats PA et al (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington\u2019s disease transgenic mice. Proc Natl Acad Sci U S A 105:15564\u201315569","journal-title":"Proc Natl Acad Sci U S A"},{"key":"250_CR269","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1124\/jpet.108.146332","volume":"328","author":"S Threlfell","year":"2008","unstructured":"Threlfell S, Sammut S, Menniti FS et al (2008) Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. J Pharmacol Exp Ther 328:785\u2013795","journal-title":"J Pharmacol Exp Ther"},{"key":"250_CR270","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1124\/jpet.108.146332","volume":"328","author":"S Threlfell","year":"2009","unstructured":"Threlfell S, Sammut S, Menniti FS et al (2009) Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. J Pharmacol Exp Ther 328:785\u2013795","journal-title":"J Pharmacol Exp Ther"},{"key":"250_CR271","doi-asserted-by":"crossref","first-page":"29722","DOI":"10.1074\/jbc.M112.372474","volume":"287","author":"RS Trevino","year":"2012","unstructured":"Trevino RS, Lauckner JE, Sourigues Y et al (2012) Fibrillar structure and charge determine the interaction of polyglutamine protein aggregates with the cell surface. J Biol Chem 287:29722\u201329728","journal-title":"J Biol Chem"},{"key":"250_CR272","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1210\/en.2007-1166","volume":"149","author":"D Tsao","year":"2008","unstructured":"Tsao D, Thomsen HK, Chou J et al (2008) TrkB agonists ameliorate obesity and associated metabolic conditions in mice. Endocrinol 149:1038\u20131048","journal-title":"Endocrinol"},{"key":"250_CR273","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1007\/s00415-011-6099-5","volume":"258","author":"SJ van den Bogaard","year":"2011","unstructured":"van den Bogaard SJ, Dumas EM, Teeuwisse WM et al (2011) Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington\u2019s disease provides in vivo evidence for impaired energy metabolism. J Neurol 258:2230\u20132239","journal-title":"J Neurol"},{"key":"250_CR274","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2967\/jnumed.110.077156","volume":"51","author":"K Van Laere","year":"2010","unstructured":"Van Laere K, Casteels C, Dhollander I et al (2010) Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med 51:1413\u20131417","journal-title":"J Nucl Med"},{"key":"250_CR275","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.expneurol.2005.07.021","volume":"196","author":"JM Van Raamsdonk","year":"2005","unstructured":"Van Raamsdonk JM, Pearson J, Rogers DA et al (2005) Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol 196:266\u2013272","journal-title":"Exp Neurol"},{"key":"250_CR276","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fnins.2013.00037","volume":"7","author":"F Vanevski","year":"2013","unstructured":"Vanevski F, Xu B (2013) Molecular and neural bases underlying roles of BDNF in the control of body weight. Front Neurosci 7:37","journal-title":"Front Neurosci"},{"key":"250_CR277","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nrd3793","volume":"12","author":"L Vecsei","year":"2013","unstructured":"Vecsei L, Szalardy L, Fulop F et al (2013) Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 12:64\u201382","journal-title":"Nat Rev Drug Discov"},{"key":"250_CR278","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000341070","volume":"91","author":"FM Velez-Lago","year":"2013","unstructured":"Velez-Lago FM, Thompson A, Oyama G et al (2013) Differential and better response to deep brain stimulation of chorea compared to dystonia in Huntington\u2019s Disease. Stereotact Funct Neurosurg 91:129\u2013133","journal-title":"Stereotact Funct Neurosurg"},{"key":"250_CR279","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.23953","volume":"27","author":"CS Venuto","year":"2012","unstructured":"Venuto CS, McGarry A, Ma Q et al (2012) Pharmacologic approaches to the treatment of Huntington\u2019s disease. Mov Disord 27:31\u201341","journal-title":"Mov Disord"},{"key":"250_CR280","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.WNL.0000090629.40891.4B","volume":"61","author":"P Verbessem","year":"2003","unstructured":"Verbessem P, Lemiere J, Eijnde BO et al (2003) Creatine supplementation in Huntington\u2019s disease: a placebo-controlled pilot trial. Neurology 61:925\u2013930","journal-title":"Neurology"},{"key":"250_CR281","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.nbd.2012.07.006","volume":"48","author":"R Vlamings","year":"2012","unstructured":"Vlamings R, Benazzouz A, Chetrit J et al (2012) Metabolic and electrophysiological changes in the basal ganglia of transgenic Huntington\u2019s disease rats. Neurobiol Dis 48:488\u2013494","journal-title":"Neurobiol Dis"},{"key":"250_CR282","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","volume":"57","author":"JP Vonsattel","year":"1998","unstructured":"Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57:369\u2013384","journal-title":"J Neuropathol Exp Neurol"},{"key":"250_CR283","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/anie.201206561","volume":"52","author":"ZM Wang","year":"2013","unstructured":"Wang ZM, Lashuel HA (2013) Discovery of a novel aggregation domain in the huntingtin protein: implications for the mechanisms of Htt aggregation and toxicity. Angew Chem Int Ed Engl 52:562\u2013567","journal-title":"Angew Chem Int Ed Engl"},{"key":"250_CR284","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/BJ20070970","volume":"408","author":"H Wang","year":"2007","unstructured":"Wang H, Peng MS, Chen Y et al (2007) Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem J 408:193\u2013201","journal-title":"Biochem J"},{"issue":"11","key":"250_CR285","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00109-013-1071-8","volume":"91","author":"EG Waterhouse","year":"2013","unstructured":"Waterhouse EG, Xu B (2013) The skinny on brain-derived neurotrophic factor: evidence from animal models to GWAS. J Mol Med (Berl) 91(11):1241\u20131247. doi:10.1007\/s00109-013-1071-8. Epub 2013 Jul 5","journal-title":"J Mol Med (Berl)"},{"key":"250_CR286","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1172\/JCI64565","volume":"122","author":"A Weiss","year":"2012","unstructured":"Weiss A, Trager U, Wild EJ et al (2012) Mutant huntingtin fragmentation in immune cells tracks Huntington\u2019s disease progression. J Clin Invest 122:3731\u20133736","journal-title":"J Clin Invest"},{"key":"250_CR287","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1073\/pnas.97.13.7202","volume":"97","author":"YD Wen","year":"2000","unstructured":"Wen YD, Perissi V, Staszewski LM et al (2000) The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc Natl Acad Sci U S A 97:7202\u20137207","journal-title":"Proc Natl Acad Sci U S A"},{"key":"250_CR288","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1073\/pnas.0308679101","volume":"101","author":"NS Wexler","year":"2004","unstructured":"Wexler NS, Lorimer J, Porter J et al (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington\u2019s disease age of onset. Proc Natl Acad Sci U S A 101:3498\u20133503","journal-title":"Proc Natl Acad Sci U S A"},{"key":"250_CR289","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cmet.2006.10.004","volume":"4","author":"P Weydt","year":"2006","unstructured":"Weydt P, Pineda VV, Torrence AE et al (2006) Thermoregulatory and metabolic defects in Huntington\u2019s disease transgenic mice implicate PGC-1alpha in Huntington\u2019s disease neurodegeneration. Cell Metab 4:349\u2013362","journal-title":"Cell Metab"},{"key":"250_CR290","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-213X-5-17","volume":"5","author":"JM Woda","year":"2005","unstructured":"Woda JM, Calzonetti T, Hilditch-Maguire P et al (2005) Inactivation of the Huntington\u2019s disease gene (Hdh) impairs anterior streak formation and early patterning of the mouse embryo. BMC Dev Biol 5:17","journal-title":"BMC Dev Biol"},{"issue":"1","key":"250_CR291","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000338635","volume":"12","author":"RC Wolf","year":"2013","unstructured":"Wolf RC, Thomann PA, Thomann AK et al (2013) Brain structure in preclinical Huntington\u2019s disease: a multi-method approach. Neurodegener Dis 12(1):13\u201322","journal-title":"Neurodegener Dis"},{"key":"250_CR292","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archneur.1981.00510070046005","volume":"38","author":"HH Wright","year":"1981","unstructured":"Wright HH, Still CN, Abramson RK (1981) Huntington\u2019s disease in black kindreds in South Carolina. Arch Neurol 38:412\u2013414","journal-title":"Arch Neurol"},{"key":"250_CR293","doi-asserted-by":"crossref","first-page":"14708","DOI":"10.1523\/JNEUROSCI.1637-10.2010","volume":"30","author":"Y Xie","year":"2010","unstructured":"Xie Y, Hayden MR, Xu B (2010) BDNF overexpression in the forebrain rescues Huntington\u2019s disease phenotypes in YAC128 mice. J Neurosci 30:14708\u201314718","journal-title":"J Neurosci"},{"key":"250_CR294","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","volume":"101","author":"A Yamamoto","year":"2000","unstructured":"Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease. Cell 101:57\u201366","journal-title":"Cell"},{"key":"250_CR295","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","volume":"109","author":"L Yang","year":"2009","unstructured":"Yang L, Calingasan NY, Wille EJ et al (2009) Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson\u2019s and Huntington\u2019s diseases. J Neurochem 109:1427\u20131439","journal-title":"J Neurochem"},{"key":"250_CR296","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1093\/hmg\/ddn281","volume":"17","author":"D Zala","year":"2008","unstructured":"Zala D, Colin E, Rangone H et al (2008) Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 17:3837\u20133846","journal-title":"Hum Mol Genet"},{"key":"250_CR297","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/sj.npp.1301537","volume":"33","author":"HT Zhang","year":"2008","unstructured":"Zhang HT, Huang Y, Masood A et al (2008) Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacol 33:1611\u20131623","journal-title":"Neuropsychopharmacol"},{"key":"250_CR298","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000321681","volume":"8","author":"SF Zhang","year":"2011","unstructured":"Zhang SF, Hennessey T, Yang L et al (2011) Impaired brain creatine kinase activity in Huntington\u2019s disease. Neurodegener Dis 8:194\u2013201","journal-title":"Neurodegener Dis"},{"key":"250_CR299","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nature06515","volume":"451","author":"W Zhao","year":"2008","unstructured":"Zhao W, Kruse JP, Tang Y et al (2008) Negative regulation of the deacetylase SIRT1 by DBC1. Nature 451:587\u2013590","journal-title":"Nature"},{"key":"250_CR300","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","volume":"90","author":"C Zuccato","year":"2010","unstructured":"Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease. Physiol Rev 90:905\u2013981","journal-title":"Physiol Rev"},{"key":"250_CR301","doi-asserted-by":"crossref","first-page":"e22966","DOI":"10.1371\/journal.pone.0022966","volume":"6","author":"C Zuccato","year":"2011","unstructured":"Zuccato C, Marullo M, Vitali B et al (2011) Brain-derived neurotrophic factor in patients with Huntington\u2019s disease. PLoS One 6:e22966","journal-title":"PLoS One"},{"key":"250_CR302","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","volume":"145","author":"D Zwilling","year":"2011","unstructured":"Zwilling D, Huang SY, Sathyasaikumar KV et al (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145:863\u2013874","journal-title":"Cell"}],"container-title":["Current Topics in Behavioral Neurosciences","Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2013_250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T23:10:04Z","timestamp":1746054604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2013_250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"ISBN":["9783662463437","9783662463444"],"references-count":302,"URL":"https:\/\/doi.org\/10.1007\/7854_2013_250","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]},"assertion":[{"value":"27 November 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}